<DOC>
	<DOCNO>NCT01971476</DOCNO>
	<brief_summary>The present trial perform accord open design determine maximum tolerable dose ( MTD ) evaluation dose-limiting toxicity ( DLT ) volasertib paediatric leukaemia solid tumour age group 2 less 12 12 less 18 year . A objective collect data safety , tolerability , toxicity , efficacy ( preliminary activity ) , pharmacokinetics pharmacodynamics volasertib paediatric cancer patient</brief_summary>
	<brief_title>Open Dose Escalating Trial Determine Maximum Tolerated Dose Paediatric Patients With Advanced Cancers Whom Therapy Known</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<criteria>Inclusion criterion : paediatric patient leukaemia advanced solid tumour include lymphoma ( age 2 less 18 year ) treatment know Lansky score &gt; 60 child 2 less 12 year Karnofsky score &gt; 60 child age 12 old life expectancy least 6 week judge investigator parent legal guardian give write informed consent inform assent suitable respective age group obtain Exclusion criterion : patient eligible antileukaemic therapy curative intent effective therapy know solid tumour therapy presence cardiac disease ( LVEF echocardiography less 25 % ) symptomatic CNS involvement malignant disease primary CNS tumour inadequate lab parameter inadequate venous access QTc prolongation pregnancy , breastfeed disease CTs might interfere evaluation safety</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>